A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet

American Journal of Physiology - Endocrinology and Metabolism

Volumn 294, Issue 5, 2008, Pages

  Tsunoda, Masaki ^a   Kobayashi, Naoki ^a   Ide, Tomohiro ^a   Utsumi, Mari ^a   Nagasawa, Michiaki ^a   Murakami, Koji ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Insulin resistance; KRP 101; Muscle lipid oxidation; Obesity

Indexed keywords

2 [[3 [N [[4 (4 FLUOROPHENOXY)PHENYL]METHYL]CARBAMOYL] 4 METHOXYPHENYL]METHYL]BUTANOIC ACID; ADIPONECTIN; FENOFIBRATE; INSULIN; KRP 101; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BUTYRIC ACID DERIVATIVE; COMPLEMENTARY DNA; DRUG DERIVATIVE; FATTY ACID; FENOFIBRIC ACID; KRP-101; LIPID; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FATTY ACID BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID DIET; LIPID OXIDATION; MALE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BLOOD; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; GENETICS; HUMAN; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RAT; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BUTYRIC ACIDS; DIETARY FATS; DNA, COMPLEMENTARY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; GENES, REPORTER; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER; LUCIFERASES; MALE; OBESITY; OXIDATION-REDUCTION; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PROCETOFEN; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATION (GENETICS);

EID: 45549095187     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00627.2007     Document Type: Article

References (44)

1. Ashwell M, Stirling D, Freeman S, Holloway BR. Immunological, histological and biochemical assessment of brown adipose tissue activity in neonatal, control and beta-stimulant-treated adult dogs. Int J Obes 11: 357-365, 1987.
2. Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 276: 1486-1493, 2001.
3. Barr VA, Malide D, Zarnowski MJ, Taylor SI, Cushman SW. Insulin stimulates both leptin secretion and production by rat white adipose tissue. Endocrinology 138: 4463-4472, 1997.
4. Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism. Endocrinology 147: 4252-4262, 2006.
5. Bodkin NL, Pill J, Meyer K, Hansen BC. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res 35: 617-624, 2003.
6. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
7. Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem 42: 3785-3788, 1999.
8. Chalkley SM, Hettiarachchi M, Chisholm DJ, Kraegen EW. Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47: 1121-1126, 1998.
9. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 279: E554-E560, 2000.
10. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290: 1084-1089, 2002.
11. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116: 337-350, 2004.
12. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
13. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3: 83-92, 2001.
14. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 3: 145-156, 2007.
15. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000.
16. Haluzik MM, Haluzik M. PPAR-alpha and insulin sensitivity. Physiol Res 55: 115-122, 2006.
17. Holloway BR, Stribling D, Freeman S, Jamieson L. The thermogenic role of adipose tissue in the dog. Int J Obes 9: 423-432, 1985.
18. Ide T, Nakazawa T, Mochizuki T, Murakami K. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 49: 521-525, 2000.
19. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
20. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861, 2005.
21. Keller H, Devchand PR, Perroud M, Wahli W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem 378: 651-655, 1997.
22. Klimcakova E, Moro C, Mazzucotelli A, Lolmede K, Viguerie N, Galitzky J, Stich V, Langin D. Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem Biophys Res Commun 358: 897-902, 2007.
23. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11: 495-499, 1988.
24. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52: 2331-2337, 2003.
25. Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 51: 130-138, 2008.
26. Lean ME, James WP, Jennings G, Trayhurn P. Brown adipose tissue uncoupling protein content in human infants, children and adults. Clin Sci (Lond) 71: 291-297, 1986.
27. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 296: 293-299, 2002.
28. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
29. Nagasawa M, Akasaka Y, Ide T, Hara T, Kobayashi N, Utsumi M, Murakami K. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells. Biochem Pharmacol 74: 1738-1746, 2007.
30. Nagasawa M, Ide T, Suzuki M, Tsunoda M, Akasaka Y, Okazaki T, Mochizuki T, Murakami K. Pharmacological characterization of a human-specific peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in dogs. Biochem Pharmacol 67: 2057-2069, 2004.
31. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53: 14-22, 1998.
32. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46: 983-988, 1997.
33. Purushotham A, Wendel AA, Liu LF, Belury MA. Maintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice. J Lipid Res 48: 444-452, 2007.
34. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 17: 431-439, 2006.
35. Roden M. Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes. Int J Obes (Lond) 29, Suppl 2: S111-115, 2005.
36. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996.
37. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87: 3023-3028, 2002.
38. Serisier S, Briand F, Ouguerram K, Siliart B, Magot T, Nguyen P. Fenofibrate lowers lipid parameters in obese dogs. J Nutr 136: 2037S-2040S, 2006.
39. Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 12: 2161-2167, 2006.
40. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998.
41. Wang M, Winneroski LL, Ardecky RJ, Babine RE, Brooks DA, Etgen GJ, Hutchison DR, Kauffman RF, Kunkel A, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters MK, Rito CJ, Rungta DK, Tripp AE, Wilson SB, Xu Y, Zink RW, McCarthy JR. Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis. Bioorg Med Chem Lett 14: 6113-6116, 2004.
42. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550, 2000.
43. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 42: 1543-1551, 2001.
44. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.